James E. Harrison
Purdue Pharma
5 Papers
94 Citations
James E. Harrison is an academic researcher from Purdue Pharma. The author has contributed to research in topics: Cannabinoid receptor & Agonist. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Kenneth J. Valenzano,Laykea Tafesse,Gary Lee,James E. Harrison,Jamie Boulet,Susan L. Gottshall,Lilly Mark,Michelle S. Pearson,Wendy S. Miller,Shen Shan,Leyana Rabadi,Yakov Rotshteyn,Suzanne M. Chaffer,Paul I. Turchin,David A. Elsemore,Mathew Toth,Lee Koetzner,Garth Whiteside +17 more
TL;DR: Data support the tenet that selective CB2 receptor agonists have the potential to treat pain without eliciting the centrally-mediated side effects associated with non-selective cannabinoid agonists, and highlight the utility of GW405833 for the investigation of CB2 physiology.
300
N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain.
James D. Pomonis,James E. Harrison,Lilly Mark,David R. Bristol,Kenneth J. Valenzano,Katharine Walker +5 more
TL;DR: The effects of BCTC on acute, inflammatory, and neuropathic pain in rats suggest a role for VR1 in persistent and chronic pain arising from inflammation or nerve injury.
291
Pharmacological characterisation of a rat model of incisional pain
Garth Whiteside,James E. Harrison,Jamie Boulet,Lilly Mark,Michelle S. Pearson,Susan L. Gottshall,Katharine Walker +6 more
TL;DR: The potency and efficacy of different classes of analgesic drugs in a rat model of postincisional pain were investigated and these compounds showed reliable efficacy across two different behavioural end points, the Randall–Selitto (paw pressure) assay and electronic von Frey.
A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Garth Whiteside,Susan L. Gottshall,Jamie Boulet,Suzanne M. Chaffer,James E. Harrison,Michelle S. Pearson,Paul I. Turchin,Lilly Mark,Augusta E. Garrison,Kenneth J. Valenzano +9 more
TL;DR: The data demonstrate that the antihyperalgesic effects of GW405833 are mediated via the cannabinoid CB2 receptor, whereas the analgesic and sedative effects are not, and suggest that the mechanism of action for GW40 5833 does not depend on the release of endogenous opioids.
98
Pharmacology of 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: A Potent, Broad-Spectrum State-Dependent Sodium Channel Blocker for Treating Pain States
Victor I. Ilyin,James D. Pomonis,Garth Whiteside,James E. Harrison,Michelle S. Pearson,Lilly Mark,Paul I. Turchin,Susan L. Gottshall,Richard B. Carter,Phong Nguyen,Derk J. Hogenkamp,Shakira Olanrewaju,Elfrida R. Benjamin,Richard M. Woodward +13 more
TL;DR: The experiments suggest that high-potency, broad-spectrum, state-dependent Na+ channel blockers will have clinical utility for treating neuropathic, inflammatory, and postsurgical pain and Optimizing the biophysical parameters of broad-Spectrum voltage-gated Na+ channels may lead to improved pain therapeutics.
35